The anti-dementia drug candidate, (-)-clausenamide, improves memory impairment through its multi-target effect.
Chu S, Liu S, Duan W, Cheng Y, Jiang X, Zhu C, Tang K, Wang R, Xu L, Wang X, Yu X, Wu K, Wang Y, Wang M, Huang H, Zhang J.
Chu S, et al. Among authors: cheng y.
Pharmacol Ther. 2016 Jun;162:179-87. doi: 10.1016/j.pharmthera.2016.01.002. Epub 2016 Jan 23.
Pharmacol Ther. 2016.
PMID: 26812265
Review.